| Literature DB >> 34353441 |
Jie Zhang1, Zhi-Wei Ye2, Kenneth D Tew2, Danyelle M Townsend3.
Abstract
Cisplatin has been a mainstay of cancer chemotherapy since the 1970s. Despite its broad anticancer potential, its clinical use has regularly been constrained by kidney toxicities. This review details those biochemical pathways and metabolic conversions that underlie the kidney toxicities. A wide range of redox events contribute to the eventual physiological consequences of drug activities.Entities:
Keywords: Alkylating agent; Antioxidants; Bioactivation; Cisplatin; Glutathione; Glutathione S-transferases; Kidney; Nephrotoxicity; Redox pathways; Transporters
Mesh:
Substances:
Year: 2021 PMID: 34353441 PMCID: PMC8963537 DOI: 10.1016/bs.acr.2021.03.008
Source DB: PubMed Journal: Adv Cancer Res ISSN: 0065-230X Impact factor: 6.242